Brief: Mira Pharmaceuticals Inc - Completes Phase 1 Dosing Of Ketamir-2 - SEC Filing
03/03/2026 21:32
March 3 (Reuters) - Mira Pharmaceuticals Inc MIRA.O: MIRA PHARMACEUTICALS INC - COMPLETES PHASE 1 DOSING OF KETAMIR-2 - SEC FILING MIRA PHARMACEUTICALS INC - NO SERIOUS ADVERSE EVENTS OR DOSE-LIMITING TOXICITIES REPORTED IN PHASE 1 TRIAL OF KETAMIR-2- SEC FILING MIRA PHARMACEUTICALS- NO CLINICALLY SIGNIFICANT DISSOCIATIVE OR PSYCHOTOMIMETIC EFFECTS OBSERVED IN PHASE 1 TRIAL OF KETAMIR-2 - SEC FILING Further company coverage: MIRA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mira Pharmaceuticals
See all newsBrief: Mira Pharmaceuticals - Alan Weichselbaum To Step Down As CFO Effective June 6, 2026 - SEC Filing
Brief: MIRA Pharmaceuticals Secures Worldwide Exclusive Rights To MIRA-55 And SKNY-1 - SEC Filing
Brief: Mira Pharmaceuticals Enters Into Amendment No 1 To Exclusive License Agreement With Miralogx
Brief: Mira Pharmaceuticals Inc - Completes Phase 1 Dosing Of Ketamir-2 - SEC Filing
Brief: Mira Pharmaceuticals Inc - Initiates Phase 1 Study Of Ketamir-2 - SEC Filing